Whitney Jones, MD, chief medical advisor at GRAIL Inc, discusses the PATHFINDER study of multi-cancer early detection testing.
Whitney Jones, MD, chief medical advisor at GRAIL Inc, discusses the implications of results from the PATHFINDER study (NCT04241796) on multi-cancer early detection (MCED) testing.
How can the results of the PATHFINDER study impact future research on MCED tests?
The PATHFINDER [trial] was our first return-of-results study, so it's really critical. About 6500 people, all very well screened, had this test done “in the wild”—so doctors got the results and decided how to work those patients up and how to evaluate them. And the critical take-home messages for this [included] the performance of the test, [which] was essentially identical to what we had demonstrated in our case-control trials that led to the formulation of the tests, and those were the CCGA [Circulating Cell-free Genome Atlas] trials. So the take-home message is, number 1, that performance is the same. The specificity remained very high, the positive predictive value remained very high—about 43%. In addition, about 70% of the cancers that we diagnosed had no screening outside of USPSTF guidelines. So again, that capacity for multi-cancer [early detection tests] to broaden the number of cancers screened beyond the 30% that we [currently] screen, in fact screening 100%, [is significant]. Number 2: Almost 50% of the cancers that we diagnosed were in stage I and stage II. Knowing that stage shift is a marker for the ability to have better outcomes with treatment was a really huge impact for that. The third piece was that we [more than] doubled the number of cancers detected by routine USPSTF screenings with the multi-cancer early detection tests. That's impacting dramatically the cancer detection rate, which is really our focus and goal: to increase the number of cancers we're finding as pre-symptomatic, earlier stage cancers, so we can have more effective treatment. Cancer is more treatable the earlier it's detected.
Do the results have enough support to impact clinical decisions? How so, or what next steps are needed to get there?
At GRAIL, we've developed an extremely robust basis, based on our scientific studies, for implementing this. That was really the impetus—we wanted to bring this amazing technology to market so we could start saving lives now. Again, even though there were only 6500 people in that study, it was shown to be safe. We essentially mirrored our performance. I think that, along with the additional studies that we've brought—the CCGA studies, and we’re involved in a huge trial with the National Health Service with over 140,000 individuals randomized into two arms. We think the data is robust and supports utilizing this in the screening environment for people who are at elevated risk of cancer, such as those aged 50 and over. We absolutely think that the test itself was robust and helped us lead into the space and really proved the concept that we had developed in our case-controlled clinical trials.
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More